Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction mFOLFOX6 With or Without Aflibercept Followed by Chemoradiation in High-Risk Locally Advanced Rectal Cancer
2014-002063-14Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Aug 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in rectal cancer (2 arms), sponsored by GEMCAD. Primary endpoint: pathological complete response rate (pCR). Started Aug 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2014-002063-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002063-14.